Beam Therapeutics (BEAM) Return on Capital Employed (2020 - 2026)
Beam Therapeutics (BEAM) reported Return on Capital Employed of 26.42% for Q1 2026, up 1123.0% year-over-year from 2.16% in Q1 2025, and up 10.53% quarter-over-quarter from 29.53% in Q4 2025.
Beam Therapeutics (BEAM) Return on Capital Employed (2020 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 7 years of Return on Capital Employed data on file, last reported at 26.42% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 26.42%, up 1123.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 26.42% (up 1123.0% YoY), and the FY2025 annual result was 32.09%, up 570.0% from the prior year.
- Return on Capital Employed improved to 26.42% in Q1 2026 per BEAM's latest filing, from 29.53% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 14.86% in Q1 2024 and troughed at 43.49% in Q4 2024.
- A 5-year average of 28.3% and a median of 29.53% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed surged 4325 bps in 2022, then slumped 2840 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 30.16% in 2022, then jumped by 50 bps to 15.09% in 2023, then sank by 188 bps to 43.49% in 2024, then jumped by 32 bps to 29.53% in 2025, then gained by 11 bps to 26.42% in 2026.
- Business Quant data shows BEAM's Return on Capital Employed at 26.42% in Q1 2026, 29.53% in Q4 2025, and 39.9% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - | -26.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.42% |
| Dec 31, 2025 | -29.53% |
| Sep 30, 2025 | -39.90% |
| Jun 30, 2025 | -35.54% |
| Mar 31, 2025 | -37.66% |
| Dec 31, 2024 | -43.49% |
| Sep 30, 2024 | -17.40% |
| Jun 30, 2024 | -16.28% |
| Mar 31, 2024 | -14.86% |
| Dec 31, 2023 | -15.09% |
| Sep 30, 2023 | -36.15% |
| Jun 30, 2023 | -33.64% |
| Mar 31, 2023 | -32.33% |
| Dec 31, 2022 | -30.16% |
| Sep 30, 2022 | -27.32% |
| Jun 30, 2022 | -23.81% |
| Mar 31, 2022 | -21.55% |
| Dec 31, 2021 | -35.61% |
| Sep 30, 2021 | -40.04% |
| Jun 30, 2021 | -50.79% |